For a middle‑aged male post‑radical prostatectomy with high‑risk pathology (positive surgical margins, extracapsular extension, seminal‑vesicle invasion, high Gleason score), is Orgovyx (relugolix) appropriate as adjuvant androgen‑deprivation therapy instead of standard injectable agents?

Adjuvant Androgen Deprivation Therapy Post-Prostatectomy: Orgovyx vs. Injectable Agents

Adjuvant hormone therapy after radical prostatectomy is not recommended for high-risk pathology features, regardless of whether you use Orgovyx (relugolix) or injectable LHRH agonists. 1

The Evidence Against Adjuvant ADT Post-Prostatectomy

The ESMO guidelines explicitly state that adjuvant hormone therapy after radical prostatectomy is not recommended for patients with positive surgical margins or extracapsular extension 1. This recommendation holds even for high-risk features like seminal vesicle invasion and high Gleason scores.

What You Should Do Instead

The appropriate management for your patient with high-risk pathology is adjuvant radiotherapy to the prostate bed, not systemic hormone therapy alone. 1, 2

• Adjuvant radiotherapy significantly improves biochemical recurrence-free survival in patients with extracapsular extension (52% vs 30% at 5 years), seminal vesicle invasion (60% vs 18%), and positive margins (64% vs 27%) compared to surgery alone 3
• Three landmark randomized trials (SWOG 8794, EORTC 22911, ARO 96-02) consistently demonstrate that adjuvant radiotherapy reduces biochemical recurrence, local recurrence, and clinical progression in patients with adverse pathologic features 2
• SWOG 8794 showed overall survival benefit with adjuvant radiation (HR 0.72; 95% CI: 0.55-0.96; P = 0.023) 1

The Specific Clinical Algorithm

Step 1: If PSA is undetectable (<0.2 ng/mL) post-prostatectomy with high-risk pathology → offer adjuvant radiotherapy within 1 year (ideally 12-16 weeks post-surgery) 2

Step 2: If PSA rises (≥0.2 ng/mL confirmed) → offer salvage radiotherapy PLUS hormonal therapy (not hormonal therapy alone) 2

Step 3: If lymph nodes are pathologically positive (pN1) → immediate ADT is indicated (Category 1 recommendation), and consider adding pelvic radiotherapy (Category 2B) 4, 2

Why Orgovyx Is Not the Right Question Here

The choice between Orgovyx and injectable agents becomes relevant only when ADT is actually indicated. For your specific scenario—adjuvant therapy post-prostatectomy with high-risk pathology but no nodal involvement—ADT monotherapy is not the standard of care. 1

When ADT Would Be Appropriate (and Then Orgovyx Could Be Considered)

If your patient had pathologically positive lymph nodes (pN1), then:

• ADT is a Category 1 recommendation 4
• Orgovyx (relugolix) is FDA-approved for advanced prostate cancer requiring at least 1 year of androgen deprivation 5
• Orgovyx achieves rapid castration (99% by Day 29) without testosterone surge, unlike LHRH agonists 5
• Orgovyx demonstrates improved cardiovascular safety compared to leuprolide in the HERO trial, with reduced major adverse cardiovascular events 6
• Orgovyx allows rapid testosterone recovery after discontinuation (55% achieve >280 ng/dL at 90 days), potentially reducing long-term ADT toxicity 5

Practical Considerations for Orgovyx

If ADT were indicated and you chose Orgovyx:

• Compliance appears acceptable (94% of days covered in real-world data), with 93% of patients reporting never missing a dose 7
• Cost is the major barrier: 50% of patients who didn't fill prescriptions cited cost as the reason 7
• No new safety signals when used in combination with androgen receptor-targeted agents like apalutamide 8
• Standard dosing is 360 mg loading dose on Day 1, then 120 mg daily 5

Critical Pitfalls to Avoid

Do not use ADT alone without radiotherapy in the post-prostatectomy setting for high-risk pathology—this provides no survival benefit and exposes patients to ADT toxicity unnecessarily 1

Do not delay adjuvant radiotherapy beyond 1 year after surgery, as efficacy declines with time and rising PSA 4

Do not confuse the adjuvant setting (undetectable PSA) with the salvage setting (rising PSA)—hormonal therapy has a role in salvage radiotherapy but not as adjuvant monotherapy 2

The Bottom Line for Your Patient

Your middle-aged male with positive margins, extracapsular extension, seminal vesicle invasion, and high Gleason score should be counseled about adjuvant radiotherapy (64-65 Gy to the prostate bed within 1 year), not adjuvant ADT with Orgovyx or any other agent. 2 If he develops biochemical recurrence later, then salvage radiotherapy plus hormonal therapy becomes appropriate. 2 If pathology had shown positive lymph nodes, then immediate ADT (potentially with Orgovyx given its favorable profile) plus consideration of pelvic radiotherapy would be indicated. 4